nach oben

Erschienen in:

01.10.2007 | Preclinical Study

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

verfasst von: Mariam A. Stoff-Khalili, Angel A. Rivera, J. Michael Mathis, N. Sanjib Banerjee, Amanda S. Moon, A. Hess, Rodney P. Rocconi, T. Michael Numnum, M. Everts, Louise T. Chow, Joanne T. Douglas, Gene P. Siegal, Zeng B. Zhu, Hans Georg Bender, Peter Dall, Alexander Stoff, Larissa Pereboeva, David T. Curiel

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Alternative and complementary therapeutic strategies need to be developed for metastatic breast cancer. Virotherapy is a novel therapeutic approach for the treatment of cancer in which the replicating virus itself is the anticancer agent. However, the success of virotherapy has been limited due to inefficient virus delivery to the tumor site. The present study addresses the utility of human mesenchymal stem cells (hMSCs) as intermediate carriers for conditionally replicating adenoviruses (CRAds) to target metastatic breast cancer in vivo.

Experimental design

HMSC were transduced with CRAds. We used a SCID mouse xenograft model to examine the effects of systemically injected CRAd loaded hMSC or CRAd alone on the growth of MDA-MB-231 derived pulmonary metastases (experimental metastases model) in vivo and on overall survival.

Results

Intravenous injection of CRAd loaded hMSCs into mice with established MDA-MB-231 pulmonary metastatic disease homed to the tumor site and led to extended mouse survival compared to mice treated with CRAd alone.

Conclusion

Injected hMSCs transduced with CRAds suppressed the growth of pulmonary metastases, presumably through viral amplification in the hMSCs. Thus, hMSCs may be an effective platform for the targeted delivery of CRAds to distant cancer sites such as metastatic breast cancer.

Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM (2004) Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 3:437–449PubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMedCrossRef

Hebda PA, Dohar JE (1999) Transplanted fetal fibroblasts: survival and distribution over time in normal adult dermis compared with autogenic, allogenic, and xenogenic adult fibroblasts. Otolaryngol Head Neck Surg 121:245–251PubMedCrossRef

Hemminki A, Kanerva A, Liu B, Wang M, Alvarez RD, Siegal GP, Curiel DT (2003) Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. Cancer Res 63:847–853PubMed

Herrlinger U, Woiciechowski C, Sena-Esteves M, Aboody KS, Jacobs AH, Rainov NG, Snyder EY, Breakefield XO (2000) Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas. Mol Ther 1:347–357PubMedCrossRef

Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B et al (2003) Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8:449–458PubMedCrossRef

Koc ON, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R, Kolodny EH, Yoseph YB, Gerson SL, Lazarus HM et al (1999) Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 27:1675–1681PubMedCrossRef

Li S, Tokuyama T, Yamamoto J, Koide M, Yokota N, Namba H (2005) Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells. Cancer Gene Ther 12:600–607PubMedCrossRef

Liu Y, Ye T, Maynard J, Akbulut H, Deisseroth A (2005) Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increases the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther 13:346–356

10.

Mathis JM, Stoff-Khalili MA, Curiel DT (2005) Oncolytic adenoviruses—selective retargeting to tumor cells. Oncogene 24:7775–7791PubMedCrossRef

11.

Namba H, Tagawa M, Miyagawa T, Iwadate Y, Sakiyama S (2000) Treatment of rat experimental brain tumors by herpes simplex virus thymidine kinase gene-transduced allogeneic tumor cells and ganciclovir. Cancer Gene Ther 7:947–953PubMedCrossRef

12.

Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT (2002). Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62:4663–4670PubMed

13.

Payne AS, Cornelius LA (2002) The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 118:915–922PubMedCrossRef

14.

Pereboeva L, Curiel DT (2004) Cellular vehicles for cancer gene therapy: current status and future potential. BioDrugs 18:361–385PubMedCrossRef

15.

Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT (2003) Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells 21:389–404PubMedCrossRef

16.

Raykov Z, Balboni G, Aprahamian M, Rommelaere J (2004) Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 109:742–749PubMedCrossRef

17.

Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM (2004) Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 11:1694–1702PubMedCrossRef

18.

Stoff-Khalili MA, Stoff A, Rivera AA, Banerjee NS, Everts M, Young S, Siegal GP, Richter DF, Wang M, Dall P et al (2005) Preclinical evaluation of transcriptional targeting strategies for carcinoma of the breast in a tissue slice model system. Breast Cancer Res 7:R1141–R1152PubMedCrossRef

19.

Stoff-Khalili MA, Stoff A, Rivera AA, Mathis JM, Everts M, Wang M, Kawakami Y, Waehler R, Mathews QL, Yamamoto M et al (2005) Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol Ther 4:1203–1210PubMed

20.

Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603–3608PubMed

21.

Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M (2004) Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593–1603PubMedCrossRef

22.

Suzuki K, Alemany R, Yamamoto M, Curiel DT (2002) The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res 8:3348–3359PubMed

23.

Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7:120–126PubMed

24.

Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832–1837PubMed

25.

Wegner SA, Ehrenberg PK, Chang G, Dayhoff DE, Sleeker AL, Michael NL (1998). Genomic organization and functional characterization of the chemokine receptor CXCR4, a major entry co-receptor for human immunodeficiency virus type 1. J Biol Chem 273:4754–4760PubMedCrossRef

26.

Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA 3rd et al (2004) Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter. Gene Ther 11:645–648PubMedCrossRef

Titel: Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma
verfasst von: Mariam A. Stoff-Khalili
Angel A. Rivera
J. Michael Mathis
N. Sanjib Banerjee
Amanda S. Moon
A. Hess
Rodney P. Rocconi
T. Michael Numnum
M. Everts
Louise T. Chow
Joanne T. Douglas
Gene P. Siegal
Zeng B. Zhu
Hans Georg Bender
Peter Dall
Alexander Stoff
Larissa Pereboeva
David T. Curiel
Publikationsdatum: 01.10.2007
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 2/2007
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-006-9449-8

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

Abstract

Purpose

Experimental design

Results

Conclusion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Experimental design

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2007

Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology

Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study

Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients

Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients

Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray

Provider’s volume and quality of breast cancer detection and treatment

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie